Trial reportJournal of human hypertension2005
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial.
Trial report in Journal of human hypertension, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.The Cochrane database of systematic reviews · 2024Pooled it
- First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.The Cochrane database of systematic reviews · 2018Pooled it
- First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus.Journal of human hypertension · 2018Pooled it
- Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.The Cochrane database of systematic reviews · 2014Pooled it
- Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.Journal of general internal medicine · 2012Pooled it
- The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.Journal of the American Society of Nephrology : JASN · 2018Trial
- Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles.Diabetologia · 2008Trial
- First-line diuretics versus other classes of antihypertensive drugs for hypertension.The Cochrane database of systematic reviews · 2023Review
- Blood pressure management in patients with type 2 diabetes mellitus.Hypertension research : official journal of the Japanese Society of Hypertension · 2017Review
- Effect of erythropoietin-stimulating agent on uremic inflammation.Journal of inflammation (London, England) · 2012Article
- Inflammation and therapy for hypertension.Current hypertension reports · 2010Review
- The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man.Vascular health and risk management · 2009Review
- New insights into complement C3 and inflammation in hypertension.Journal of human hypertension · 2007Article
- Towards understanding the aetiology and pathophysiology of human hypertension: where are we now?Journal of human hypertension · 2006Article
- Insights into human hypertension: the role of endothelial dysfunction.Journal of human hypertension · 2006Article
- Statins and hypertension.Journal of human hypertension · 2006Article
- Do increased plasma adrenomedullin levels in normotensive subjects precede hypertension?Journal of human hypertension · 2006Article
- Endothelial progenitor cells in the vascular pathophysiology of hypertension: arterial stiffness, ageing and more.Journal of human hypertension · 2006Article
- Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials.Journal of human hypertension · 2005Article
- Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension?Journal of human hypertension · 2005Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals. A total of 70 hypertensive type II diabetic individuals were treated with three antihypertensive strategies in a randomized, double-blind, double-dummy design. Blood pressure was titrated to levels below 130/85 mmHg or a decrease in systolic pressure of 10% with a diastolic pressure below 85 mmHg. After titration, patients were treated for 12 months. Mean blood pressures changed from 157/93, 151/94 and 149/93 at baseline to 135/80, 135/82 and 131/80 mmHg after titration in the hydrochlorothiazide (n=24), candesartan (n=24) and lisinopril (n=22) groups. About 70% reached target blood pressures. However, only 45% had blood pressures <130/85 mmHg. Urinary albumin excretion and levels of soluble vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 decreased (GEE regression coefficients, -2.40 mg/24 h (P<0.001), -85 ng/ml (P=0.01) and -50 ng/ml (P=0.02)), but brachial artery endothelium-dependent and -independent vasodilation and levels of von Willebrand factor and C-reactive protein did not change (GEE regression coefficients, 0.21 mm (P=0.07), 0.04 mm (P=0.43), 0.04 IU/ml (P=0.33) and -1.15 mg/l (P=0.64)). No differences in outcome variables between treatment groups were observed. These data show that achievement of target blood pressures below 130/85 mmHg in hypertensive type II diabetes is difficult. Aggressive antihypertensive therapy can improve urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals, regardless of the type of antihypertensive therapy used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.